Valeo Financial Advisors LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 202,705 shares of the biopharmaceutical company's stock after selling 15,085 shares during the quarter. Valeo Financial Advisors LLC's holdings in Pfizer were worth $5,378,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of PFE. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer during the fourth quarter valued at approximately $26,000. Gladius Capital Management LP boosted its stake in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 38,015 shares in the last quarter. Teachers Insurance & Annuity Association of America bought a new position in shares of Pfizer during the third quarter valued at approximately $35,000. Joseph Group Capital Management boosted its stake in shares of Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 771 shares in the last quarter. Finally, Sugar Maple Asset Management LLC bought a new position in shares of Pfizer during the fourth quarter valued at approximately $43,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.06% of the stock is owned by corporate insiders.
Shares of Pfizer stock traded down $0.15 during trading on Friday, hitting $25.50. 33,055,417 shares of the company's stock were exchanged, compared to its average volume of 37,577,760. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business has a 50-day simple moving average of $26.28 and a 200-day simple moving average of $27.58. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The stock has a market capitalization of $144.48 billion, a price-to-earnings ratio of 18.08, a PEG ratio of 0.64 and a beta of 0.64.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the company earned $0.10 earnings per share. The firm's revenue for the quarter was up 24.7% on a year-over-year basis. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.75%. Pfizer's payout ratio is presently 121.99%.
A number of equities analysts have recently issued reports on PFE shares. Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Bank of America restated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, StockNews.com downgraded shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and a consensus target price of $31.92.
Get Our Latest Stock Report on PFE
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.